Back to results
US 12,600,755 B2Granted
Cobra 1/NELF-B as a booster for efficacy of CD8+ T cell-based therapy
AssigneeThe George Washington University a Congressionally Chartered Not-for-Profit Corporation
InventorsRong Li, Bogang Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of generating a T cell comprising a transgene integrated at a first site within the genome of the T cell, wherein the transgene encodes a polypeptide that is a subunit of a negative elongation factor (NELF) complex. The T cells can be administered to treat cancer and infectious disease.
Claims19
A method of treating a cancer in a subject in need thereof, comprising:
- administering to the subject a therapeutically effective amount of a population of T cells modified to overexpress one or more subunits of the negative elongation factor (NELF) complex.
Dependencies are inferred from the claim text.